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Abstract Background Global differences exist in the management of atrial ﬁbrillation (AF), and
cultural differences may inﬂuence patients’ expectations and perceptions of health-
care. This survey investigated whether country-speciﬁc differences in patients’ percep-
tions of AF and oral anticoagulation (OAC) exist and if recent stroke inﬂuences these
perceptions.
Methods Cross-sectional survey of 937 adults with nonvalvular AF receiving OAC for
stroke prevention was conducted across United States, Canada, Germany, France, and
Japan. Thirty-minute online interviews conducted between April and November 2015
included AF patients with recent stroke, and newly diagnosed AF and established AF,
both without recent stroke.
Results U.S. patients and those with recent stroke perceived AF as more serious (54.0
and 55.2%, respectively) and were more concerned about stroke (50.0 and 68.0%,
respectively). Japanese patients were more likely to perceive AF as not serious (41.0%),
but 50.4% were frequently concerned about stroke. Patients in the United States,
Canada, and Germany and those without recent stroke preferred to be involved in OAC
treatment decisions (either shared decision making or patient’s choice), while French
and Japanese patients and those with recent stroke preferred their doctor to choose.
For all country groups, stroke prevention was the most important factor when
choosing OAC.
Conclusion In this international cohort of AF patients, country-speciﬁc differences
exist in patients’ perceptions of AF, concerns about stroke, and preference for
involvement in OAC treatment decisions; recent experience of stroke signiﬁcantly
inﬂuenced patients’ values and preferences regarding AF and treatment. Stroke
prevention was rated as the most important factor when choosing OAC treatment.
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Introduction
Recent clinical guidelines on the management of atrial
ﬁbrillation (AF) advocate inclusion of patients’ preferences
in treatment decisions.1–4 However, global differences exist
in the management of AF, and cultural differences may
inﬂuence patient’s expectations and perceptions of health-
care. Most research regarding patient’s values and prefer-
ences in AF patients has been in relation to antithrombotic
therapy.5–11However, patient’s perspectives vary from study
to study and may be related to actual differences in prefer-
ences, the composition of the cohort (patient’s age, sex,
socioeconomic status, comorbidities), whether patients are
already receiving oral anticoagulation (OAC), knowledge of
AF and stroke, the way in which risk information is pre-
sented, and the manner in which responses are
elicited.8–10,12,13
Generally, AF patients have poor understanding about AF
and its trajectory, and a paucity of knowledge about the
increased risk of stroke and beneﬁts/risks of OAC.8,9,12,14–17
Although a recent prospective survey in eight European
countries demonstrated that among AF patients taking
OAC, 90% knew that OAC was “to thin the blood,” only 26%
were aware that OAC increased the risk of all bleeding,
including major bleeding.18 Furthermore, patients’ indivi-
dual circumstances, previous experiences, and current
health status will inﬂuence their knowledge and help deter-
mine their willingness to take treatments.8,12,19 Indeed, a
prospectiveU.S. survey12 found that knowledgeof strokewas
better among AF patients with previous stroke, and stroke
survivors were more willing to take OAC.
Studies initiated before the non–vitamin K antagonist oral
anticoagulant (NOAC) era have generally demonstrated that
patients place greater importance on avoidance of a stroke
rather than bleeding and other OAC-related issues (i.e., regular
monitoring, drug–food–alcohol interactions).5,7,11,20,21 Since
the introduction of the NOACs, there has been renewed inter-
est in the values and preferences regarding OAC of AF patients.
Only a few studies have compared patient’s preferences for
vitamin K antagonists (VKAs) and NOACs6,22,23 and examined
the attributes that patientsperceive as importantwhen choos-
ing OAC.6,12,22–24 Three studies6,12,23 reported that patients
ratestrokepreventionas themost important attribute forOAC,
whileothers rateeaseofadministration22andavailabilityofan
antidote24 as of highest importance; however, differences in
themethodologyof thesestudiesmayaccount for thedisparity
in the ﬁndings. In addition, these studies did not examine
patient’s perceptions of AF and stroke, or knowledge about
stroke, which may drive these preferences.
We performed a prospective, international survey to
investigate whether country-speciﬁc differences exist in
patient’s perceptions of AF, concerns about stroke, stroke
knowledge, preferences for OAC treatment decisions, self-
reported OAC medication adherence, and the attributes of
OAC affecting treatment choice. We also examined whether
AF patients who experienced a recent stroke differ in their
perceptions about AF, stroke, and OAC treatment compared
with AF patients who were free from recent stroke.
Materials and Methods
Study Design
This was an international, prospective, cross-sectional study
of AF patients aged 18 years, receiving OAC for stroke
prevention. Patients with mechanical valves or scheduled
for heart valve surgery were excluded. Patients were
recruited from ﬁve countries—United States, Canada, Ger-
many, France, and Japan—through consumer panels, physi-
cian/nurse referral, and patient associations. These countries
were chosen as they already had wide NOAC usage at the
time of the survey and were regarded as representative of
key regions (North America, South-East Asia, and Europe).
Patients were recruited depending on their AF status and
stratiﬁed into three groups according to predeﬁned quotas:
(1) AF with recent stroke (6 months, regardless of when AF
was diagnosed); (2) newly diagnosed AF without recent
stroke (diagnosed with AF 6 months [United States,
Canada, France, Germany], or 12 months in Japan); and
(3) established AF without recent stroke (AF diagnosed 7–
24 months previously [United States, Canada, France, Ger-
many], or 1–3 years previously in Japan).
Qualitative interviews were performed with 16 AF
patients (6 in Germany, 10 in the United States) prior to
release of the online survey, to test and optimize the read-
ability of questions and patient information. For the online
survey, a total of 517,692 individuals were contacted,
517,203 of those through country-speciﬁc consumer panels
(6 or 7 different panels per country). A total of 489 were
contacted via phone (all countries) or face-to-face (France,
Japan) from physician/nurse/pharmacist referral. Referral
from patient associations was more common outside of
North America; online forums/social media were employed
in Germany and Japan. Of 89,481 individuals who connected
to the online survey, 7,889 eligible AF patients were identi-
ﬁed, of which 937 (11.9%) completed the 30-minute survey
in their native language between April and November 2015.
The questionnaire consisted of 22 questions to elicit demo-
graphic data (age, sex, country/region, highest level of edu-
cation), past medical history, and the outcomes of interest.
All data were collected anonymously and analyzed in an
aggregated fashion.
For the current analyses, the outcomes of interest were
patient’s perceptions of the seriousness of AF and their
concerns about stroke, patient’s knowledge about stroke,
self-reported adherence to OAC, patient’s preference for
involvement in OAC treatment choice, and attributes of
OAC affecting treatment choice by the patient. Assessment
of stroke knowledge is summarized in ►Fig. 1. In addition,
patients were asked how familiar they were with standar-
dized information about AF and stroke, but this was separate
to the assessment of stroke knowledge. The modiﬁed Ran-
kin’s score (mRS) in patients with a recent stroke was self-
reported according to predeﬁned mRS scale descriptors.25
Sample sizes/quotas were determined according to feasi-
bility estimates and to allowmeaningful comparisons across
the three predeﬁned AF groups and countries. Participants
gave informed consent by completing and submitting the
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online survey. The survey was conducted in accordance with
the principles of the Declaration of Helsinki.
Statistical Analysis
Descriptive statistics are presented as mean and standard
deviation (SD) for normally distributed continuous variables;
categorical data are presented as actual count and percentage.
Analyses were conducted by country and separately by AF
status at baseline (AF with recent stroke vs. AF without recent
stroke). To examine differences between countries and
between AF groups, means were compared using t-tests and
categorical datawere compared using chi-squared tests. Since
heterogeneity was present in the data, we used the unequal
variances t-test (Welch–Satterthwaite test) to detect differ-
ences in means of samples; this test is robust for analyzing
equality of means when the homogeneity assumption is not
satisﬁed. Data were analyzed using Sawtooth: Lighthouse
Studio v9.0.1 and SPSS PASW Statistics, version 18, with
p-values <0.05 considered statistically signiﬁcant. p-values
comparing more than three subgroups relate to data of one
group compared with the data of all other groups together.
Results
In total, 937 AF patients were recruitedwith an overall mean
(SD) age of 54.3 (16.6) years; 37.1%were female. One-third of
patients were from the United States, with between 15 and
18% recruited from Canada, Japan, France, and Germany.
Signiﬁcantly more American women and signiﬁcantly fewer
Japanese women were recruited compared with other coun-
tries. Signiﬁcantly more Americans and Japanese were edu-
cated to university/technical college level. Stroke risk was
lower among patients from France and Germany and highest
among patients from Japan (►Table 1).
Patient’s Perceptions about AF, Stroke, and OAC
Medication by Country
AF was perceived by American patients as more serious and
by French and German patients as less serious, while 41% of
Japanese patients perceived AF as not serious (►Table 2).
There were no differences in stroke knowledge between the
ﬁve countries (►Table 2). American patients were more
concerned about stroke, while French patients were less
frequently concerned about stroke (►Table 2).
Self-reported OAC adherence was high overall, but Amer-
ican patients reported greater OAC adherencewhile Japanese
patients reported poorer adherence (►Table 2). Themajority
of French and Japanese patients (60 and 58%, respectively)
preferred their doctor to choose OAC treatment; in contrast,
62, 59, and 66% of American, Canadian, and German patients,
respectively, preferred shared decision making or to choose
the OAC themselves (►Table 2). Stroke prevention was the
most important factor for 47.4% of AF patients when choos-
ing OAC (►Fig. 2), followed by risk of major bleeding. Dosing
frequency was rated as most important by only 8.2% of the
patients. Japanese patients were more concerned about
other side effects and dosing frequency than patients from
other countries (►Fig. 2). Ranking of OAC attributes demon-
strated a very similar patternwhen analyzed byage (<65 and
65 years), sex, or educational level (data not shown).
Patient’s Perceptions about AF, stroke, and OAC
Medication among AF Patients with Recent Stroke
versus those with No Recent Stroke
Recent stroke occurred in 194 (20.7%) patients; one-third of
patients were female. Patients with recent stroke were
signiﬁcantly younger (47.6 [17.5] years vs. 56.0 [15.9] years,
respectively) and had a signiﬁcantly higher CHA2DS2-VASc
score (4.3 [1.3] vs. 2.2 [1.5]) than patients without a recent
stroke (both p < 0.001). Of those with a recent stroke, 149 of
193 (77.2%) had a moderate to severe disability (mRS: 2–5);
mean mRS (SD) score was 2.5 (1.2).
Patientswith recent strokewere signiﬁcantlymore likely to
perceive AF as an extremely serious or very serious condition
and were often more concerned about stroke than those
without a recent stroke (►Table 3). Thosewith less functional
disability after a stroke (mRS score: 0–1) were more likely to
perceiveAFasnot serious comparedwith thosewithmoderate
to severe disability (18.2 vs. 3.4%, respectively). Good levels of
stroke knowledge were signiﬁcantly lower in patients with a
recent stroke compared with those without (9.8 vs. 22.1%,
respectively, p < 0.001). There were high levels of self-
Fig. 1 Scoring system to categorize patients’ level of stroke knowledge (from open-ended questions).
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reported adherence to OAC therapy, but recent stroke survi-
vors reported signiﬁcantly lower adherence to OAC compared
withpatientswithouta recent stroke.AFpatientswitha recent
stroke preferred their doctor to make the OAC treatment
choice, whereas patients without a recent stroke were more
likely to prefer being involved in the decision (►Table 3).
Stroke preventionwas themost important factor for all AF
patients when choosing OAC, followed by major bleeding
(►Fig. 2). AF patients with a recent stroke were less con-
cerned about stroke prevention and more concerned about
dietary restrictions, taking medication with/without food,
dosing frequency, and antidote availability compared with
those without recent stroke (►Fig. 3).
Discussion
In this prospective, international survey of AF patients
receiving OAC, there were signiﬁcant between-country dif-
ferences in patient’s perceptions about AF, stroke, and OAC
treatment, and differences between AF patients with and
without recent stroke. Concern about stroke was greater
among thosewith recent stroke,while stroke knowledgewas
poorer. Importantly, AF patients with recent stroke preferred
their doctor to make the OAC treatment choice, while
patients without recent stroke preferred involvement in
this decision making. Finally, stroke prevention was rated
as the most important factor when choosing OAC, regardless
of country of residence, whether they had experienced a
recent stroke, and age, sex, or educational level.
In this survey, country differences in patient’s perceptions
were evident. American patients perceived AF more seriously
and were more concerned about stroke than French patients.
Japanese patients were more likely to perceive AF as not
serious, but half were highly concerned about stroke. Patients
in the United States, Canada, and Germany preferred to be
involved in the OAC treatment decision (either shared decision
making or patient’s choice), while those in France and Japan
preferred their doctor to choose. Patients with recent stroke
and those with greater functional disability perceived AF as
moreserious.Countrydifferencesmayreﬂectdifferentcultural
backgrounds, such as how the physician’s role and responsi-
bility isgenerally perceived ina society, but also speciﬁc factors
such as educational programs on AF and/or anticoagulation or
differences in healthcare systems. Although generic education
on AF should be given to all AF patients, our ﬁndings suggest
that country-speciﬁc approaches may be required for certain
aspects, suchas thediscussionaboutpotential consequencesof
AF to enable patients to understand the seriousness of AF.
Importantly, our results suggest that physicians should be
aware about the patients’ desire to be involved in the OAC
treatment decision and act accordingly when talking with the
patient as this differs between countries.
Before the initiation of the present study, only a few studies
had examined patient’s preferences regarding OAC,7,11,14 pre-
dominantly relating to patient’s preferences for VKAs11 as
most were conducted before NOACs became available. Given
the greater choice of OAC, the differing clinical risk proﬁle
(efﬁcacy/safety), differing dosing regimens, and other
Table 1 Patient baseline demographic and clinical characteristics overall and by country
Characteristic Overall
(n ¼ 937)
USA
(n ¼ 322)
Canada
(n ¼ 145)
Japan
(n ¼ 139)
France
(n ¼ 171)
Germany
(n ¼ 160)
Mean (SD) age, y 54.3 (16.6) 56.0 (16.9)a 52.8 (17.4) 59.1 (11.8)b 49.6 (18.8)b 53.0 (14.6)
65 y 309 (33.0) 128 (39.8)b 45 (31.0) 48 (34.5) 45 (26.3)a 43 (26.9)
Female, n (%) 348 (37.1) 151 (46.9)b 55 (37.9) 32 (23.0)b 56 (32.7) 54 (33.8)
Mean (SD) CHA2DS2-VASc
score
2.6 (1.7) 2.8 (1.6)b 2.7 (1.5) 3.1 (2.1)b 2.1 (1.7)b 2.3 (1.4)b
CHA2DS2-VASc 2 (female);
1 (male), n (%)
796 (85.0) 280 (87.0) 129 (89.0) 123 (88.5) 130 (76.0)b 134 (83.8)
Educational level,c n (%)
University/technical college 391 (41.8) 178 (55.3)b 55 (37.9) 83 (60.1)b 38 (22.2)b 37 (23.1)b
Community college 263 (28.1) 75 (23.3)a 46 (31.7) 31 (22.5) 55 (32.2) 56 (35.0)a
High-school diploma 255 (27.2) 68 (21.1)b 36 (24.8) 21 (15.2)b 63 (36.8)b 67 (41.9)b
No school leaving certiﬁcate 27 (2.9) 1 (0.3)b 8 (5.5)a 3 (2.2) 15 (8.8)b 0a
AF groups, n (%)
AF with recent stroke 194 (20.7) 63 (19.6) 31 (21.4) 35 (25.2) 34 (19.9) 31 (19.4)
Recent AF, no recent stroke 342 (36.5) 123 (38.2) 50 (34.5) 50 (36.0) 59 (34.5) 60 (37.5)
Established AF, no recent
stroke
401 (42.8) 136 (42.2) 64 (44.1) 54 (38.8) 78 (45.6) 69 (43.1)
Abbreviations: AF, atrial ﬁbrillation; SD, standard deviation.
ap < 0.05.
bp < 0.001 versus other countries pooled.
cOne patient did not report educational level.
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Table 2 Patients’ perceptions about AF and stroke, level of stroke knowledge, self-reported adherence to OAC, and preference for
involvement in OAC treatment choice overall and by country
Overall
(n ¼ 937)
USA
(n ¼ 322)
Canada
(n ¼ 145)
Japan
(n ¼ 139)
France
(n ¼ 171)
Germany
(n ¼ 160)
Perception of
seriousness
of AF (%)
Extremely/very
serious
39.4 54.0a 40.0 35.3 28.7a 24.4a
Somewhat
serious
41.6 33.9a 47.6 23.7a 55.0a 53.1a
Not at all/not
serious
19.0 12.1a 12.4b 41.0a 16.4 22.5
Concern
about
stroke (%)
Often/always 43.4 50.0a 36.6 50.4 32.2a 42.5
Occasionally 45.4 41.0 55.2a 34.5a 52.6b 46.9
Never/don’t
know
11.2 9.0 8.3 15.1 15.2 10.6
Knowledge of
stroke (%)
Good/moderate 47.4 45.3 49.7 48.2 42.7 53.8
Low/none 52.6 54.7 50.3 51.8 57.3 46.2
Self-reported
adherence to
OAC
Always take as
prescribed
79.9 83.5b 84.8 67.4a 80.1 78.8
Often take as
prescribed
17.4 15.2 13.8 26.8a 18.1 16.2
Sometimes take
as prescribed
2.4 0.9b 1.4 5.1b 1.2 5.0b
Rarely take as
prescribed
0.3 0.3 0 0.7 0.6 0
Patient’s
preference
for involve-
ment in OAC
treatment
choice
Patient’s choice 19.6 19.9 22.1 18.0 14.6 23.8
Patient–doc-
tor’s choice
35.6 41.9a 37.2 23.7a 25.7a 42.5b
Doctor’s choice 44.7 38.2a 40.7 58.3a 59.6a 33.8a
Abbreviations: AF, atrial ﬁbrillation; OAC, oral anticoagulation.
ap < 0.001 versus other countries pooled.
bp < 0.05.
Fig. 2 The most important factor in the choice of oral anticoagulation rated by atrial ﬁbrillation patients for the cohort overall and by country.
ap < 0.05 versus other countries pooled. bp < 0.001 versus other countries pooled. Percentages do not always equal to 100 due to rounding.
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attributes of the NOACs (reversibility, taking with/without
food, etc.)—all of which may affect patient’s preference for
OAC treatment—this study was advantageous. More recently,
there have been a few published studies on patient’s prefer-
ences for OAC including the NOACs,6,18,22–24,26 but the major-
ity have recruited AF patients from just one country, have
much smaller sample sizes, and included more selected AF
populations; to our knowledge, the only exception to this was
the European Heart Rhythm Association (EHRA) survey.18,26
The present survey recruited a large sample of AF patients
from ﬁve countries (three outside Europe), including newly
diagnosed AF patients and those with recent experience of
stroke, thereby offering a more diverse picture of patient’s
perceptions of AF and preferences for OAC treatment.
Perceptions of Atrial Fibrillation and Concerns about
Stroke
Previous studies have demonstrated that patients often do
not perceive AF as a serious condition and are not aware of
the increased risk of stroke associated with AF.8,9,12,14–16
Generally, patients’ knowledge about AF and stroke preven-
tion is poor,8,9,12,15,16 and educational level does not always
Table 3 Patients’ perceptions about AF and stroke, level of stroke knowledge, self-reported adherence to OAC, and preference for
involvement in OAC treatment choice overall and by recent stroke/no recent stroke
Recent stroke
(n ¼ 194)
No recent stroke
(n ¼ 743)
Perception of seriousness of AF (%) Extremely/
very serious
55.2a 35.3
Somewhat serious 37.6 42.7
Not at all/
not serious
7.2a 22.1
Concern about stroke (%) Often/always 68.0a 37.0
Occasionally 28.4a 49.8
Never/
don’t know
3.6a 13.2
Knowledge of stroke (%) Good 9.8a 22.1
Moderate 27.3 28.0
Low 30.4 29.6
None 32.5a 20.3
Familiarity with information on AF and
stroke (%)b
Familiar 53.1 35.3
Self-reported adherence to OAC Always take as prescribed 73.6c 81.6
Often take as prescribed 21.2 16.4
Sometimes take as prescribed 4.7c 1.7
Rarely take as prescribed 0.5 0.3
Patient’s preference for involvement in
OAC treatment choice
Patient’s choice 22.7 18.8
Patient–doctor’s choice 18.6a 40.1
Doctor’s choice 58.6a 41.0
Abbreviations: AF, atrial ﬁbrillation; OAC, oral anticoagulation.
ap < 0.001.
b8–10 on a 10-point scale; see supplement.
cp < 0.05.
Fig. 3 Themost important factor in the choice of oral anticoagulation
rated by atrial ﬁbrillation patients with a recent stroke (A) and those
without a recent stroke (B). ap < 0.05 versus no recent stroke.
bp < 0.001 versus no recent stroke. Percentages do not always equal
to 100 due to rounding.
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differentiate thosewho know the purpose of OAC from those
who do not.18,26However, themajority of studies report that
patients are concerned about the risk of stroke and wish to
avoid this.7,10,20,21 Indeed, a Canadian study7 elicited health
utilities using an iPad questionnaire and found that patients
viewed minor stroke as slightly worse than a major bleed,
whereas a moderate stroke was viewed as virtually equiva-
lent to death and amajor stroke as worse than death. Studies
have generally shown that patients are prepared to accept a
higher risk of OAC-related bleeding to prevent stroke.7,10,21
How AF patients are informed about their risk proﬁle and
available treatments can affect treatment choice, and this is
likely to be highly variable in clinical practice. A recent EHRA
survey27 found that 51% of centers had structured education
programs for stroke prevention for AF patients. According to
respondents, patient’s preferences for OAC were considered
important whenmaking treatment decisions in themajority
of centers (64.7%). Although some centers have resources/
programs in place to educate patients about their stroke risk
proﬁle and treatment, there was a disparity in what was
delivered and delivery strategies employed.27
Participation in the Oral Anticoagulation Decision
In line with the recommended shared decision-making
approach,28–32 it is evident from the present study that a
large proportion of AF patients prefer to be involved in the
choice regarding OAC (55.3% overall), while many others
prefer the physician to choose the OAC. However, country-
speciﬁc differences and experience of stroke can affect a
patient’s desire to participate in decision making and may
reﬂect different sociocultural role expectations in the
patient–physician interaction; educational level did not
inﬂuence this preference. One small cross-sectional study
reported that 98% would like to participate in the OAC
decision;24 however, several factors, including the small
sample size, an all-male U.S. veteran cohort, and a mixture
of patients with and without AF—with some of them receiv-
ing OAC—limit these ﬁndings. A qualitative study20 of AF
patients requiring OAC showed that AF patients prefer con-
sultations that provide the opportunity tomake an informed
decision, and that they favor an individual approach based on
their risk proﬁle (stroke and bleeding) and the attributes that
are important to them.
Although some patients may not wish to participate in the
treatment decision, at the very least an approach that
encourages patient–physician dialogue should be advocated
to increase the likelihood of healthcare professionals (HCPs)
imparting adequate information to the patient in order for
them to understand the condition and the need for OAC
treatment and, hence, the potential implications of treatment
decisions (advantages and disadvantages). A contemporary
EHRA consensus document highlights the importance of edu-
cation of AF patients8 and repetition of information over time,
from various sources.
Self-reported Adherence to Oral Anticoagulation
Adherence to OAC medication is essential to minimize
thromboembolic or hemorrhagic complications, and physi-
cians are often concerned about patient adherence to
OAC.33–35 Overall, self-reported adherence to OAC was high
in the present study (79.9%). American patients reported
greater adherence to OAC (83.5%), while Japanese patients
reported poorer adherence (67.4%), which inversely corre-
lated with the perception of seriousness of AF (41% of
Japanese patients believed AF was not serious compared
with only 12% of American patients). Patients with recent
stroke reported lower adherence, which may be due to
cognitive impairment, or reﬂect limited trust in the efﬁcacy
of OAC or vice versa being a cause for the patient to have
suffered a (hemorrhagic) stroke. Self-reported adherence to
OAC was around 75% in a recent EHRA survey of 1,147
patients with AF from eight European countries;26 adher-
ence was signiﬁcantly lower in men versus women and
younger versus older patients (<65 vs. 65 years). Other
studies employing more objective measures of adherence
(e.g., proportion of days medication is taken as prescribed
based on prescriptions or electronic monitoring devices)
36–39 demonstrates that NOAC adherence is generally 80%
or better, but adherence rates vary between cohorts and by
the deﬁnition, and measure, of adherence employed.
Factors Important in Oral Anticoagulation Choice
The present study found that patients place greater impor-
tance on avoidance of a stroke than bleeding, and on
efﬁcacy over factors associated with treatment burden
(e.g., dosing frequency, dietary restrictions, taking the
medication with or without food) when ranking attributes
of OAC treatment. This ﬁnding concurs with most other
studies,6,23,25,40 including a systematic review of patient’s
values and preferences in decision making for antithrom-
botic therapy.11 A study of AF patients with and without
stroke demonstrated that reducing the risk of ischemic
stroke was the primary factor for OAC treatment choice,
followed by the medication with least side effects, then
intracranial hemorrhage, then ease of use (e.g., once-daily
dosing), and ﬁnally cost.12
A recent Canadian survey6 of 266 AF patients receiving
OAC (warfarin or NOACs) for stroke prevention found that
views on importance of OAC attributes differed between
patients and physicians. Another multicenter German study
of AF patients receiving uninterrupted OAC over the previous
3 months (either VKA or rivaroxaban)22 employed discrete
choice experiment methodology to rate (yes/no) the treat-
ment-related attributes of OAC preferred. Patients preferred
OAC treatment that was easy to administer (no bridging,
once daily, no food interactions, without international nor-
malized ratio checks/dose adjustment), and less distance to
travel to their HCP. However, this study did not include
efﬁcacy and safety attributes among the choices, which is
problematic given that these factors are likely to affect which
attributes the patient perceives as “most important” andmay
alter treatment preferences. A Swiss prospective, observa-
tional, cross-sectional study (PRiSMA-AF [AF Patient Prefer-
ences toward NOAC versus VKA Treatment: A Patient
Preference Study]) employing the same methodology and
attributes as the study by Böttger et al22 is also examining AF
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patients’ preferences for OAC (VKA and the four NOACs). In a
smaller study of U.S. veterans,24 the most important factors
associated with opting for a particular OAC (from most to
least important) were availability of an antidote, quality of
life, physician recommendation, length of time available in
the marketplace, more information before the decision, and
lower stroke risk.
Limitations
All patients in the present study were receiving OAC and
therefore their previous experiences (good or bad) with OAC
could have inﬂuenced their responses. Patients may have
wanted to prevent cognitive dissonance (internal mental
conﬂict) and therefore replied so that their responses
matched their current medication, or may have given the
answer they felt was required rather than their true pre-
ference (social desirability bias). The opportunistic sam-
pling strategy based on patients’ willingness to complete an
online survey may have biased the sample toward being
younger (and more technology-savvy), as evident from the
mean age of the cohort, and may have inﬂuenced the
ﬁndings and importance of certain attributes. Therefore,
the ﬁndings may not be representative of older AF patients
or those patients not receiving OAC. Also, respondents may
be more knowledgeable about AF and OAC treatment than
“general” AF patients, and therefore more willing to volun-
teer to participate in a survey on preferences and knowl-
edge, limiting the generalizability of the results. However,
this study recruited a large number of patients from several
countries, where differences in the management of AF and
cultural differences in the perception of healthcare may
affect the outcomes of interest, and therefore the results
may be more representative of AF patients globally. Further-
more, preferences for OAC attributes were independent of
age, sex, and educational level. In addition, this study
included a range of AF patients, those with a recent stroke,
newly diagnosed, and established AF, as different experi-
ences of living with AF, OAC treatment exposure, and the
adverse consequences of AF (i.e., a recent stroke) will likely
affect patient’s perceptions and treatment preferences, as
demonstrated by other studies.6,12,22,24
Conclusion
Country-speciﬁc differences exist in AF patients’ perceptions
of AF, concerns about stroke, and preference for involvement
in OAC treatment decisions; recent experience of stroke also
signiﬁcantly inﬂuenced patients’ perceptions of AF and
stroke, and preference for involvement in the OAC decision.
With the availability of NOACs, physicians have greater
choice for OAC, which differ in terms of their clinical proﬁle
(risk/beneﬁt), dosing regimen (once vs. twice daily), and
other attributes; however, patient’s preferences concerning
anticoagulation therapy in this context have only been partly
evaluated. Regardless of country of residence or whether
they had experienced a recent stroke, all patients rated
stroke prevention as the most important factor when choos-
ing OAC treatment. Enhancing physician–patient dialogue is
important to educate patients about AF and treatment
options and to inform physicians about patients’ preferred
level of involvement in treatment decisions, as this is likely to
increase patient’s satisfaction, whichmay result in improved
adherence. The ﬁndings of this survey could be used to
inform patient–physician communication training and
patient education programs.
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